Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Liabilities from Discontinued Operations: 2020

  • Agios Pharmaceuticals' Liabilities from Discontinued Operations was N/A to $261.3 million in Q4 2020 from the same period last year, while for Dec 2020 it was $261.3 million, marking a year-over-year change of. This contributed to the annual value of $261.3 million for FY2020, which is N/A change from last year.
  • Latest data reveals that Agios Pharmaceuticals reported Liabilities from Discontinued Operations of $261.3 million as of Q4 2020.
  • Agios Pharmaceuticals' 5-year Liabilities from Discontinued Operations high stood at $261.3 million for Q4 2020, and its period low was $261.3 million during Q4 2020.
  • In the last 1 years, Agios Pharmaceuticals' Liabilities from Discontinued Operations had a median value of $261.3 million in 2020 and averaged $261.3 million.